Pharmacogenetic interactions of medications administered for weight loss in adults : a systematic review and meta-analysis
Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Pharmacogenomics - 24(2023), 5 vom: 01. Apr., Seite 283-295 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
BouSaba, Joelle [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 18.04.2023 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.2217/pgs-2022-0192 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM355044412 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM355044412 | ||
003 | DE-627 | ||
005 | 20240402235554.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2217/pgs-2022-0192 |2 doi | |
028 | 5 | 2 | |a pubmed24n1361.xml |
035 | |a (DE-627)NLM355044412 | ||
035 | |a (NLM)36999540 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a BouSaba, Joelle |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacogenetic interactions of medications administered for weight loss in adults |b a systematic review and meta-analysis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.04.2023 | ||
500 | |a Date Revised 02.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a GLP-1 agonist | |
650 | 4 | |a bupropion | |
650 | 4 | |a gene | |
650 | 4 | |a individualized | |
650 | 4 | |a naltrexone | |
650 | 4 | |a pharmacogenomic | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Naltrexone |2 NLM | |
650 | 7 | |a 5S6W795CQM |2 NLM | |
650 | 7 | |a Bupropion |2 NLM | |
650 | 7 | |a 01ZG3TPX31 |2 NLM | |
650 | 7 | |a Peptides |2 NLM | |
650 | 7 | |a Venoms |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
650 | 7 | |a 89750-14-1 |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
650 | 7 | |a ANKK1 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
700 | 1 | |a Vosoughi, Kia |e verfasserin |4 aut | |
700 | 1 | |a Dilmaghani, Saam |e verfasserin |4 aut | |
700 | 1 | |a Prokop, Larry J |e verfasserin |4 aut | |
700 | 1 | |a Camilleri, Michael |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 5 vom: 01. Apr., Seite 283-295 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:01 |g month:04 |g pages:283-295 |
856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2022-0192 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 5 |b 01 |c 04 |h 283-295 |